Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

While maintaining its revenue forecast of $58 billion to $61 billion, the company expects EPS of $20.78 and $22.28, down from $22.50 to $24 per share. ... Eli Lilly's stock isn't cheap.

Eli Lilly (NYSE: LLY) sells a broad ... After all, from today's $28 billion market, the forecast figure represents a 239% increase. ... Before you buy stock in Eli Lilly, consider this: ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

Lilly affirmed its full-year revenue guidance, but lowered its profit forecasts. Last quarter , it said it expected 2025 revenue between $58.0 to $61.0 billion, with EPS from $22.05 to $23.55, and ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...

Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.